Clinical management of localized undifferentiated sinonasal carcinoma: our experience and review of the literature

Anticancer Drugs. 2019 Mar;30(3):308-312. doi: 10.1097/CAD.0000000000000707.

Abstract

Undifferentiated sinonasal carcinoma (SNUC) is defined as a small round blue cell tumor that is immunohistochemically distinct from other sinonasal malignancies, such as lymphoma, mucosal melanoma, nasopharyngeal carcinoma, neuroendocrine carcinoma, and olfactory neuroblastoma. SNUCs are very aggressive malignancies, provoking quick destruction of the splanchnocranium structures. Being a very rare neoplasm, there are no prospective clinical trials assessing their treatment strategies, so lots of data are derived by small retrospective trials. Tri-modality treatments (namely those treatments which use together surgery, radiation therapy and chemotherapy) are now considered the best of care for this category of poor prognosis tumors, and whenever possible they should be employed. Despite the tri-modality treatments and the multidisciplinary management, SNUCs are characterized by poor prognosis with a median overall survival reaching 14 months. Ameliorating radiotherapy techniques and performing therapies adapted to the genetics of the disease could represent a promising strategy of therapy in the near future. In this report, we have presented our experience, describing the treatment and the prognosis of four patients seen at our Institution. Moreover, we have performed a review of the literature analyzing the now available therapy options and the possible future strategies.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Carcinoma / pathology
  • Carcinoma / therapy*
  • Combined Modality Therapy
  • Disease Management
  • Humans
  • Male
  • Maxillary Sinus Neoplasms / pathology
  • Maxillary Sinus Neoplasms / therapy*
  • Middle Aged
  • Prognosis

Supplementary concepts

  • Sinonasal undifferentiated carcinoma